Chugai Pharmaceutical Co., Ltd. (CUP0) - Net Assets
Based on the latest financial reports, Chugai Pharmaceutical Co., Ltd. (CUP0) has net assets worth €2.03 Trillion EUR as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.47 Trillion) and total liabilities (€442.86 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.03 Trillion |
| % of Total Assets | 82.06% |
| Annual Growth Rate | 14.27% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.97 |
Chugai Pharmaceutical Co., Ltd. - Net Assets Trend (2021–2025)
This chart illustrates how Chugai Pharmaceutical Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chugai Pharmaceutical Co., Ltd. (2021–2025)
The table below shows the annual net assets of Chugai Pharmaceutical Co., Ltd. from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €2.03 Trillion | +6.53% |
| 2024-12-31 | €1.90 Trillion | +16.97% |
| 2023-12-31 | €1.63 Trillion | +14.12% |
| 2022-12-31 | €1.42 Trillion | +19.90% |
| 2021-12-31 | €1.19 Trillion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chugai Pharmaceutical Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.03 Trillion | 100.00% |
| Total Equity | €2.03 Trillion | 100.00% |
Chugai Pharmaceutical Co., Ltd. Competitors by Market Cap
The table below lists competitors of Chugai Pharmaceutical Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Schlumberger Limited
SA:SLBG34
|
$77.51 Billion |
|
Synopsys Inc
NASDAQ:SNPS
|
$77.57 Billion |
|
Ecolab Inc
NYSE:ECL
|
$77.83 Billion |
|
Royal Caribbean Cruises Ltd
NYSE:RCL
|
$77.85 Billion |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
$76.36 Billion |
|
INVESTOR B (FRIA) O.N.
F:IVSD
|
$75.72 Billion |
|
Investor AB ser. B
ST:INVE-B
|
$75.38 Billion |
|
Vinci S.A.
PA:DG
|
$75.08 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chugai Pharmaceutical Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,901,499,000,000 to 2,025,732,000,000, a change of 124,233,000,000 (6.5%).
- Net income of 434,012,000,000 contributed positively to equity growth.
- Dividend payments of 299,419,000,000 reduced retained earnings.
- Share repurchases of 6,000,000 reduced equity.
- New share issuances of 142,000,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €434.01 Billion | +21.42% |
| Dividends Paid | €299.42 Billion | -14.78% |
| Share Repurchases | €6.00 Million | -0.0% |
| Share Issuances | €142.00 Million | +0.01% |
| Other Changes | €-10.50 Billion | -0.52% |
| Total Change | €- | 6.53% |
Book Value vs Market Value Analysis
This analysis compares Chugai Pharmaceutical Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €722.50 | €21.60 | x |
| 2022-12-31 | €866.25 | €21.60 | x |
| 2023-12-31 | €988.01 | €21.60 | x |
| 2024-12-31 | €1155.56 | €21.60 | x |
| 2025-12-31 | €1230.91 | €21.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chugai Pharmaceutical Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.42%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 34.50%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.22x
- Recent ROE (21.42%) is below the historical average (22.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 25.50% | 30.31% | 0.65x | 1.30x | €184.19 Billion |
| 2022 | 26.29% | 29.72% | 0.67x | 1.31x | €231.99 Billion |
| 2023 | 20.02% | 29.29% | 0.58x | 1.19x | €162.91 Billion |
| 2024 | 20.37% | 33.09% | 0.53x | 1.16x | €197.17 Billion |
| 2025 | 21.42% | 34.50% | 0.51x | 1.22x | €231.44 Billion |
Industry Comparison
This section compares Chugai Pharmaceutical Co., Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,185,812,264,983
- Average return on equity (ROE) among peers: 9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chugai Pharmaceutical Co., Ltd. (CUP0) | €2.03 Trillion | 25.50% | 0.22x | $76.91 Billion |
| Bayer Aktiengesellschaft (BAYA) | $31.90 Billion | 14.21% | 1.58x | $38.90 Billion |
| Bayer AG NA (BAYN) | $12.31 Billion | -10.22% | 2.04x | $45.18 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $33.87 Billion | 12.78% | 0.31x | $10.18 Billion |
| EH3 (EH3) | $459.28 Million | -8.45% | 0.46x | $258.63 Million |
| JCR Pharmaceuticals Co., Ltd. (JCR) | $52.41 Billion | 7.20% | 0.81x | $459.04 Million |
| PT Kalbe Farma Tbk (LCLA) | $8.50 Trillion | 22.58% | 0.33x | $2.09 Billion |
| Ono Pharmaceutical Co. Ltd (ON4) | $529.62 Billion | 9.49% | 0.15x | $6.58 Billion |
| Otsuka Holdings Co. Ltd (OS1) | $1.51 Trillion | 9.99% | 0.34x | $25.67 Billion |
| Recordati Industria Chimica e Farmaceutica S.p.A (RER1) | $1.03 Billion | 28.11% | 1.00x | $10.43 Billion |
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal … Read more